Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008964562> ?p ?o ?g. }
- W2008964562 endingPage "874" @default.
- W2008964562 startingPage "859" @default.
- W2008964562 abstract "Introduction: The development of pharmacogenetic-based clinical practice guidelines for the use of anti-Parkinson's disease drugs requires, as a pre-requisite, the identification and validation of genetic biomarkers. These biomarkers are then used as surrogate endpoints. This review analyzes potential genetic biomarkers which can be used to improve anti-Parkinson's disease therapy. Areas covered: The authors present an overview of current knowledge of pharmacogenetic implications of anti-Parkinson's disease drugs, including genes coding for the corresponding drug-metabolizing enzymes and drug targets. The gene/drug pairings with the strongest potential for pharmacogenetic recommendations include: CYP2C19/benztropine, COMT/levodopa and entacapone, CYP2B6/selegiline, UGT1A/entacapone, DRD2/ropinirole, pramipexole and cabergoline, and DRD3/ropinirole and pramipexole. Evidence supporting the effect of substrates, inhibitor or inducers for drug specific metabolizing enzymes in anti-Parkinson's disease drug response includes CYP1A2 in the response to ropinirole and rasagiline, and CYP3A4 in the response to bromocriptine, lisuride, pergolide and cabergoline. The authors present and discuss the current information on gene variations according to the 1000 genomes catalog and other databases with regards to anti-Parkinson's disease drugs. They also review and discuss the clinical implications of these variations. Expert opinion: The goal of pharmacogenomic testing for anti-Parkinson's disease drugs should be conservative and aimed at selecting determined drugs for determined patients. However, much additional research is still needed to obtain reliable pre-prescription tests." @default.
- W2008964562 created "2016-06-24" @default.
- W2008964562 creator A5065070649 @default.
- W2008964562 creator A5077352921 @default.
- W2008964562 creator A5081399911 @default.
- W2008964562 creator A5087736170 @default.
- W2008964562 date "2013-04-09" @default.
- W2008964562 modified "2023-10-17" @default.
- W2008964562 title "Anti-Parkinson's disease drugs and pharmacogenetic considerations" @default.
- W2008964562 cites W1066238792 @default.
- W2008964562 cites W1497836925 @default.
- W2008964562 cites W1524431861 @default.
- W2008964562 cites W1605023214 @default.
- W2008964562 cites W1965128384 @default.
- W2008964562 cites W1968996734 @default.
- W2008964562 cites W1971304404 @default.
- W2008964562 cites W1975171688 @default.
- W2008964562 cites W1977784412 @default.
- W2008964562 cites W1978461968 @default.
- W2008964562 cites W1979487868 @default.
- W2008964562 cites W1982123542 @default.
- W2008964562 cites W1982305247 @default.
- W2008964562 cites W1983886526 @default.
- W2008964562 cites W1985205555 @default.
- W2008964562 cites W1987178620 @default.
- W2008964562 cites W1988447636 @default.
- W2008964562 cites W1991656466 @default.
- W2008964562 cites W1993885194 @default.
- W2008964562 cites W1995699580 @default.
- W2008964562 cites W1996395058 @default.
- W2008964562 cites W1996661746 @default.
- W2008964562 cites W2000135012 @default.
- W2008964562 cites W2007202520 @default.
- W2008964562 cites W2009028781 @default.
- W2008964562 cites W2010914303 @default.
- W2008964562 cites W2011961184 @default.
- W2008964562 cites W2017783406 @default.
- W2008964562 cites W2021887821 @default.
- W2008964562 cites W2022208588 @default.
- W2008964562 cites W2023120986 @default.
- W2008964562 cites W2026117122 @default.
- W2008964562 cites W2027290828 @default.
- W2008964562 cites W2030459377 @default.
- W2008964562 cites W2031759800 @default.
- W2008964562 cites W2032716720 @default.
- W2008964562 cites W2034000948 @default.
- W2008964562 cites W2037381733 @default.
- W2008964562 cites W2040397508 @default.
- W2008964562 cites W2042005699 @default.
- W2008964562 cites W2042174203 @default.
- W2008964562 cites W2048118864 @default.
- W2008964562 cites W2052323065 @default.
- W2008964562 cites W2059504441 @default.
- W2008964562 cites W2061661903 @default.
- W2008964562 cites W2064073780 @default.
- W2008964562 cites W2067876467 @default.
- W2008964562 cites W2068575259 @default.
- W2008964562 cites W2068780263 @default.
- W2008964562 cites W2071608414 @default.
- W2008964562 cites W2072232675 @default.
- W2008964562 cites W2073213000 @default.
- W2008964562 cites W2079694187 @default.
- W2008964562 cites W2081558811 @default.
- W2008964562 cites W2082551494 @default.
- W2008964562 cites W2082712042 @default.
- W2008964562 cites W2082720966 @default.
- W2008964562 cites W2083894069 @default.
- W2008964562 cites W2084409189 @default.
- W2008964562 cites W2086295825 @default.
- W2008964562 cites W2089122277 @default.
- W2008964562 cites W2090055848 @default.
- W2008964562 cites W2090991802 @default.
- W2008964562 cites W2097549898 @default.
- W2008964562 cites W2100462891 @default.
- W2008964562 cites W2116232595 @default.
- W2008964562 cites W2116255206 @default.
- W2008964562 cites W2120754845 @default.
- W2008964562 cites W2123597421 @default.
- W2008964562 cites W2129532498 @default.
- W2008964562 cites W2131996201 @default.
- W2008964562 cites W2140718540 @default.
- W2008964562 cites W2149414643 @default.
- W2008964562 cites W2152727843 @default.
- W2008964562 cites W2153368992 @default.
- W2008964562 cites W2156592390 @default.
- W2008964562 cites W2157071131 @default.
- W2008964562 cites W2157150618 @default.
- W2008964562 cites W2158640488 @default.
- W2008964562 cites W2169480634 @default.
- W2008964562 cites W4211223857 @default.
- W2008964562 cites W4252830707 @default.
- W2008964562 doi "https://doi.org/10.1517/17425255.2013.789018" @default.
- W2008964562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23565891" @default.
- W2008964562 hasPublicationYear "2013" @default.
- W2008964562 type Work @default.
- W2008964562 sameAs 2008964562 @default.
- W2008964562 citedByCount "45" @default.
- W2008964562 countsByYear W20089645622013 @default.